Clinical trials: Glucagon
Obesity
Bariatric Surgery Combined With GLP-1RA: A Multicenter Study.
Obese patients exhibit considerable heterogeneity and complex comorbidities, making long-term effective management challenging with single therapies.
- Trial name
- BS-GLP (NCT07732738)
- Testing
- BS-GLP1RA group, BS group
- Where
- 7 sites in China
- Volunteers
- 400 people
- Sponsor
- China-Japan Friendship Hospital
Ischemic Stroke, Transient Ischemic Attack
Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus
The purpose of this study is to assess the safety and efficacy of glucagon-like peptide-1 (GLP-1) analogue liraglutide in the treatment of acute minor stroke (National Institute of Health stroke scale, NIHSS ≤ 3) or high-risk…
- Conditions
- Ischemic Stroke, Transient Ischemic Attack, Type 2 Diabetes Mellitus
- Trial name
- LAMP (NCT03948347)
- Testing
- Liraglutide
- Where
- China
- Volunteers
- 1,708 people
- Sponsor
- First Affiliated Hospital of Jinan University
Insulin Resistance, Satiety
Gut Hormone Response After Paleolithic-type Meals
The effects of two palaeolithic-type meals will be assessed with respect to a panel of gut hormones, satiety, blood glucose and insulin levels as compared to a meal constructed along the lines of the world Health Organisation…
- Trial name
- FooA2 (NCT01999504)
- Testing
- PAL-2, TFH-1, Reference
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Unilever R&D
Normal Healthy Volunteer, Safety After Oral Intake
A Research Study to Evaluate BLX-7006 in Healthy Adults
This study will test an oral medicine called BLX-7006, which acts like the hormone Glucagon-like Peptide-1 (GLP-1) to help control blood sugar and body weight. Current GLP-1 medicines are given by injection.
- Trial name
- NCT07140055
- Testing
- BLX-7006
- Where
- Australia
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Biolexis Therapeutics
Ischemic Stroke
Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy
Endovascular thrombectomy (EVT) is a procedure that improves recovery for people who suffer from a stroke by removing blood clots from large blood vessels in the brain.
- Trial name
- LEAST (NCT07511543)
- Testing
- Semaglutide
- Volunteers
- 100 people
- Sponsor
- Population Health Research Institute
Type 1 Diabetes, Blood Glucose, Low
The Effect of Rapid and Slow Glucose Fall on the Subsequent Glucose Production in People With Type 1 Diabetes
In the effort of better understanding the glucose control in people with type 1 diabetes, in-depth insight into the physiology of hepatic glucose production and its influencing factors is essential.
- Conditions
- Type 1 Diabetes, Blood Glucose, Low, Glucose Metabolism Disorders
- Trial name
- RaSlo-19 (NCT04098549)
- Testing
- Rapid lowering of plasma glucose, Slow lowering of plasma glucose
- Where
- Denmark
- Volunteers
- 10 people
- Sponsor
- Steno Diabetes Center Copenhagen
Acute Ischemic Stroke, Large Vessel Occlusion
Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment
The goal of this clinical trial is to learn if semaglutide works to treat acute ischemic stroke (AIS). It will also learn about the safety of semaglutide in AIS.
- Conditions
- Acute Ischemic Stroke, Large Vessel Occlusion, Neuroprotective Drugs, Endovascular Treatment
- Trial name
- GALLOP2 (NCT06788626)
- Testing
- Semaglutide 0.5 mg, Standard medical treatment
- Where
- China
- Volunteers
- 390 people
- Sponsor
- Wei Hu
Diabetes Mellitus Type 2, Metabolic Syndrome
Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients
The most important cause of mortality amongst DM2 patients is cardiovascular disease. An early finding of cardiovascular disease in DM2 and obesity is diastolic dysfunction.
- Conditions
- Diabetes Mellitus Type 2, Metabolic Syndrome, Cardiovascular Disease, Diastolic Dysfunction
- Trial name
- MAGNA VICTORIA (NCT01761318)
- Testing
- Liraglutide
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- Leiden University Medical Center
Diabetes Mellitus, Diabetes Mellitus, Type 2
Glucagon Like Peptide 1 Receptor (GLP1R) Expression and Beta-cell Mass in Patients With Type 2 Diabetes
Validation of the exendin-based beta cell imaging technique in patients with type 2 diabetes
- Trial name
- GLP1R-T2D (NCT04733508)
- Testing
- 111In-DTPA-exendin-4, IRDye800CW-exendin-4
- Where
- Netherlands
- Volunteers
- 28 people
- Sponsor
- Radboud University Medical Center
Glucose Metabolism Disorders, Obesity
To Determine the Effect of GLP1 on Cognitive Function, Brain Glucose Metabolism and Neuroplasticity.
To test the hypothesis that GLP1 can exert favourable effects on multiple aspects of brain function. To this purpose, the investigator determine whether chronic increase in GLP1 concentration as it occurs after bariatric surgery…
- Conditions
- Glucose Metabolism Disorders, Obesity, Degenerative Brain Disorder
- Trial name
- NCT03414333
- Testing
- RYGB, GLP-1
- Where
- Italy
- Volunteers
- 14 people
- Sponsor
- University of Pisa
Liver Disease
Intravenous-Morphine and Glucagon-Usage Enhanced MR Cholangiography
Morphine can induce constriction of sphincter of oddi and glucagon can facilitate bile secretion and dilatation of bile duct. We conduct this randomized double blinded study to evaluate the effect of enhancement in MRCP using…
- Trial name
- NCT00155376
- Testing
- morphine and glucagon
- Where
- Taiwan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Kidney Transplant Recipients
The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients
The study aims to determine the short-term efficacy, mechanisms and safety of 12 weeks of dapagliflozin and semaglutide combination therapy in 20 KTR, with and without T2D.
- Trial name
- HALLMARK (NCT05938712)
- Testing
- Dapagliflozin 10 MG, Semaglutide, 1.0 mg/mL
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University Health Network, Toronto
Endocrine System Diseases
Gastric and Intestinal Satiation in Obese and Normal Weight Healthy People
The purpose of this study is to determine the reciprocal control between gastric functions and intestinal parameters in the development of satiation in obese people.
- Trial name
- NCT01456572
- Testing
- ensure plus, standardized test meal
- Where
- Switzerland
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Diabetes Mellitus, Type 1, Hypoglycemia
Comparison of Ease of Use and Acceptability of Intranasal and Injectable Glucagon Among Providers Administering it to Children or Adolescents With Type 1 Diabetes (BETTER-ING)
Background : The benefits of good glycemic control are clearly established. However, achieving glycemic targets comes at the expense of the risk of hypoglycemia.
- Trial name
- NCT05395000
- Testing
- Videos, Simulation, Interview
- Where
- Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- CHU de Quebec-Universite Laval
Transfusion Dependent Beta Thalassemia
Glucagon-Like Peptide 1 Receptor Agonist in Diabetes Mellitus Management in Children and Adolescents With Transfusion-Dependent Thalassemia
Blood transfusion and iron-chelation therapy have prolonged and improved the quality of life in patients with β-thalassemia. The improvement was mainly due to the decrease in mortality from heart failure Such a treatment…
- Trial name
- NCT07370922
- Testing
- Dulaglutide 0.75Mg/0.5Ml Inj Pen, control group (insulin)
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Ain Shams University
Type 2 Diabetes
The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 Inhibitors
In normal physiology, glucagon from pancreatic alpha cells plays an important role in maintaining glucose homeostasis via its regulatory effect on hepatic glucose production.
- Trial name
- NCT02792400
- Testing
- LY2403021, Standardised liquid meal, Linagliptin
- Where
- Denmark
- Volunteers
- 24 people
- Sponsor
- University Hospital, Gentofte, Copenhagen
Diabetes Mellitus, Type 2
The Effect of Combination of Mosapride and DPP-4 Inhibitor on Plasma Concentration of Incretin Hormones
The aim of this study is to investigate the effects of combined administration of mosapride as modulator of gastrointestinal motility and DPP-4 inhibitor on secretion of gut hormone such as glucagon-like peptide-1 (GLP-1) and…
- Trial name
- NCT02180334
- Testing
- Mosapride citrate, Linagliptin, Acetaminophen (paracetamol)
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- Seoul National University Hospital
Diabetes Mellitus Type 1
Trial to Compare the Relative Pharmacodynamic Properties of Different Glucagon Dosages
The ultimate goal of the PCDIAB project is to develop a bi-hormonal pump (insulin and glucagon) substituting for the pancreas and facilitating tight euglycemic control in patients with T1DM.
- Trial name
- NCT01916265
- Testing
- Glucagon
- Where
- Germany
- Volunteers
- 6 people
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH
PreDiabetes
Insulin and Insulin Pulses During Fasting
Fasting hyperglycemia contributes disproportionately to nonenzymatic glycosylation and the microvascular complications of type 2 diabetes.
- Trial name
- NCT06424015
- Testing
- Intralipid and heparin, Saline
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Critically Ill, Hypoglycemia
The Efficacy of Glucagon Like Peptide (GLP) - 1(7-36) Amide for Glycemic Control in Critically Ill Patients
The goal of this present proposal is to examine the efficacy of GLP-1 administered to control blood glucose in critically ill patients.
- Trial name
- NCT00798590
- Testing
- Glucagon-Like Peptide-1, Saline
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Johns Hopkins University